 Genetic Technologies Limited ASX: GTG; NASDAQ: GENE is to commence accelerating development of a polygenic risk score PRS test to predict an individuals risk of developing life-threatening complications should they become infected with COVID-19. Dr George Muchnicki CEO said GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to analyse the early, available genomic and phenotypic data from those COVID-19 patients with a view to developing a comprehensive predictive model to identify those patients most likely to require hospitalization, should they become infected with the COVID-19 virus. 